LUPRON DEPOT-PED IS THE
#1* PRESCRIBED GnRHa FOR CENTRAL PRECOCIOUS PUBERTY (CPP) IN THE US1

GnRH agonists are standard of care for
treatment of CPP2,3

alttext
Over 30 years experience

with a proven efficacy and safety profile4†


alttext
The only GnRHa with an
18+ year safety study including long-term follow-up data
(1-month dosing)5
alttext
1 brand with the flexibility to individualize CPP treatment with 1-, 3-, and 6-month dosing options6

*Data sourced as of February 2023.
†FDA approved in 1993.

GnRHa=gonadotropin-releasing hormone agonist.

References: 1. Data on file, AbbVie Inc. IQVIA NSP, 2023. 2. Carel JC, Eugster EA, Rogol A, et al. Consensus statement on the use of gonadotropin-releasing hormone analogs in children. Pediatrics. 2009;123(4):e752-e762. 3. Nabhan ZM, Walvoord EC. Treatment of gonadotropin‐dependent precocious puberty. In: Pescovitz OH, Walvoord EC, eds. When Puberty Is Precocious: Scientific and Clinical Aspects. Totowa, NJ: Humana Press; 2007:345-362. 4. Drugs@FDA: FDA-approved drugs. US Food and Drug Administration. Accessed March 24, 2023. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020263. 5. Lee PA, Neely EK, Fuqua J, et al. Efficacy of leuprolide acetate 1-month depot for central precocious puberty (CPP): growth outcomes during a prospective, longitudinal study. Int J Pediatr Endocrinol. 2011;2011(1):7. doi:10.1186/1687-9856-2011-7. 6. LUPRON DEPOT-PED [package insert]. North Chicago, IL: AbbVie Inc.